Heparin-induced thrombocytopenia in cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 7, 2011, Pages 781-787

  Miriovsky, Benjamin J ^a   Ortel, Thomas L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Heparin; Thrombocytopenia

Indexed keywords

ARGATROBAN; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CISPLATIN; GEMCITABINE; HEPARIN; HIRULOG; IRINOTECAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MITOMYCIN; THALIDOMIDE; WARFARIN;

ANTICOAGULATION; ARTICLE; CANCER PATIENT; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; NEOPLASM; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 79960075528     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0063     Document Type: Article

References (41)

1. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a metanalysis. Blood 2005;106;2710-2715. (Pubitemid 41510744)
2. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006;355:809-817. (Pubitemid 44285586)
3. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (eighth edition). Chest 2008;133:340S-380S.
4. Ban-Hoefen M, Francis C. Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital. Thromb Res 2009;124:189-192.
5. Warkentin TE, Sheppard JA, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006;108:2937-2941.
6. Francis JL, Palmer GJ III, Moroose R, et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 2003;75:17-22. (Pubitemid 36099015)
7. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. Annu Rev Med 2010;61:77-90.
8. Lyman GH. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer 2009;115:5637-5650.
9. Perry MC, ed. The Chemotherapy Sourcebook. 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2008.
10. Hitron A, Steinke D, Sutphin S, et al. Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors. J Oncol Pharm Pract; in press.
11. Elliott MA, Nichols WL. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Mayo Clin Proc 2001;76:1154-1162. (Pubitemid 33034602)
12. Levi M. Therapeutic options in patients with DIC and cancer. Pathophysiol Haemost Thromb 2003;33:S46-47.
13. Olivera GBF, Crespo E, Becker RC, et al. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008;168:94-102.
14. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost 2005;94:132-135. (Pubitemid 40974717)
15. Smythe MA, Koerber JM and Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007;131:1644-1649. (Pubitemid 46981615)
16. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003;101:2955-2959. (Pubitemid 36857979)
17. Prandoni P, Siragusa S, Girolami B, et al. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005;106:3049-3054. (Pubitemid 41565898)
18. Prandoni P, Falanga A, Piccioli A. Cancer, thrombosis and heparin-induced thrombocytopenia. Thromb Research 2007;120:S137-140.
19. Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 2004;76:240-244. (Pubitemid 38828843)
20. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153. (Pubitemid 36818784)
21. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129. (Pubitemid 46218703)
22. Kakkar AK, Levine M, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcomes Study (FAMOUS). J Clin Oncol 2004;22:1944-1948. (Pubitemid 41095187)
23. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488. (Pubitemid 35303914)
24. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84:1099-1103.
25. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135. (Pubitemid 46218704)
26. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-1072. (Pubitemid 44826932)
27. Mayo DJ, Cullinane AM, Merryman PK, et al. Serologic evidence of heparin sensitization in cancer patients receiving heparin flushes of venous access devices. Support Cancer Care 1999;7:425-427. (Pubitemid 29489196)
28. Greinacher A, Eichler P, Lubenow N, et al. Heparin- induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-851. (Pubitemid 30616845)
29. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010;8:2642-2650.
30. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-765.
31. Streiff MB, Bockenstedt PL, Cataland SR, et al. NCCN Clinical Practice Guidelines in Oncology: Venous Thromboembolic Disease. Version 2, 2011. Available at: http://www.nccn.org/professionals/physician-gls/pdf/vte.pdf Accessed December 11, 2010.
32. Price EA, Hayward CP, Moffat KA, et al. Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost 2007;98:1357-1361. (Pubitemid 350239110)
33. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005;106:3791-3796. (Pubitemid 41739014)
34. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007;5:1666-1673. (Pubitemid 47091409)
35. Pouplard C, Amiral J, Borg JY, et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999;111:700-706. (Pubitemid 29200959)
36. Warkentin TE, Sheppard JA, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005;146:341-346. (Pubitemid 41712020)
37. Lubenow N, Eichler P, Lietz T, et al. Lepirudin in patients with heparin-induced thrombocytopenia-results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005;3:2428-2436. (Pubitemid 41727158)
38. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003;108:2062-2065. (Pubitemid 37337579)
39. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-1856. (Pubitemid 36960936)
40. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843. (Pubitemid 32328395)
41. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507. (Pubitemid 126335970)